Gabapentin and Rapidity of Recovery Among Patients Undergoing Minimally Invasive Ambulatory Uro-Oncologic Surgeries.
Eleni KohilakisMelissa AsselJoanna SerafinMeghana MehtaTaylor M McCreadyHanae K TokitaPatrick J McCormickAndrew Julian VickersSigrid V CarlssonVincent P LaudoneAnoushka M AfonsoPublished in: Urology practice (2024)
Our confidence intervals did not include clinically meaningful benefits from gabapentin, when used with an ERAS protocol, in terms of length of stay or perioperative opioid use. These results support the omission of gabapentin from ERAS protocols for minimally invasive uro-oncologic surgeries.